Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
There is a close relationship between the gut microbiota and metabolic disorders. In this study, acute administration of the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide to mice increased the cecal levels of caseinolytic protease B, a component of Escherichia coli , and of norepinephrine. Chemical sympathectomy blocked these events. Norepinephrine was found to pass into the intestinal lumen in vitro. c-Fos staining of the intermediolateral nucleus was identified as indirect evidence of sympathetic nervous system activation of the intestinal tract by GLP-1RA. Under normal conditions, the increase in E. coli did not affect the host. However, in mice with colitis, bacterial translocation was observed with attenuation of tight junction gene expression. This is the first study to investigate the unique underlying mechanisms related the effects of GLP-1RA on changes in the gut bacterium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Liraglutide increases NE levels in cecal contents via activation of sympathetic nerves. (A) Relative expression of ClpB in cecal contents in saline and medetomidine (α2 receptor agonist [α2RA]) groups with or without acute liraglutide administration (saline control, n = 7; saline liraglutide, n = 6; α2RA control, n = 5; α2RA liraglutide, n = 5). (B) Measurement of norepinephrine concentrations in cecal contents and plasma in saline and medetomidine groups with or without acute liraglutide administration (saline control, n = 4; saline liraglutide, n = 5; α2RA control, n = 5; α2RA liraglutide, n = 8). (C) Relative expression of ClpB in cecal contents with or without acute liraglutide administration under bilateral adrenalectomy (ADX) (control-ADX, n = 8; liraglutide-ADX, n = 8). (D) Measurement of norepinephrine concentrations in cecal contents and plasma with or without acute liraglutide administration under ADX (control-ADX, n = 4; liraglutide-ADX, n = 4). All values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant by two-way ANOVA with multiple comparison test (A and B) or non-paired t-test (C and D). All figures were drawn using GraphPad Prism 7 (www.graphpad.com) and Microsoft’s PowerPoint 2016 (www.microsoft.com).](https://figures.cochat.ai/paper-figures/f3d6aad4503c43138f6bdafb69a5cf63/effects-of-glp-1-receptor-agonist-on-changes-in-the-gut-bacterium-and-the-figure-2.jpg)



![Figure 6 In DSS colitis, liraglutide promotes bacterial translocation. (A) Correlation between the relative expression of ClpB in cecal contents and occludin in cecal tissue in mice with DSS colitis with or without acute liraglutide administration (total, n = 18; liraglutide, n = 11). (B) ClpB positive rate in the spleen under DSS colitis conditions in wild-type (WT) mice and TLR4KO mice with or without acute liraglutide administration (WT control, n = 7; WT liraglutide, n = 9; TLR4KO control, n = 5; TLR4KO liraglutide, n = 4). (C) Cecal occludin gene expressions according to ClpB positivity (bacterial translocation [BT]) under DSS colitis conditions in wild-type (WT) mice and TLR4KO mice (WT BT-positive, n = 6; WT BT-negative, n = 10; TLR4KO BT-positive, n = 8). All values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant by linear regression analysis (A), two-way ANOVA with multiple comparison test (B), and one-way ANOVA with multiple comparison test (C). The coefficient of determination is denoted as R2. All figures were drawn using GraphPad Prism 7 (www.graphpad.com) and Microsoft’s PowerPoint 2016 (www.microsoft.com).](https://figures.cochat.ai/paper-figures/ef84caf5196641bb925151c1786b8b2f/effects-of-glp-1-receptor-agonist-on-changes-in-the-gut-bacterium-and-the-figure-6.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A systematic review of 25 studies (n = 1362) demonstrated that zinc supplementation improved glycemic control, reducing fasting blood glucose, postprandial blood glucose, and HbA1c, as well as lipid parameters, including total cholesterol, lowdensity lipoprotein cholesterol (LDL-c), and triglycerides in individuals with T2DM [289].”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [289]
In the citing paper
“A systematic review of 25 studies (n = 1362) demonstrated that zinc supplementation improved glycemic control, reducing fasting blood glucose, postprandial blood glucose, and HbA1c, as well as lipid parameters, including total cholesterol, lowdensity lipoprotein cholesterol (LDL-c), and triglycerides in individuals with T2DM [289].”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [289]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 62 · Cited by 59
Metadata
- Authors
- Kato, S., Sato, T., Fujita, H., Kawatani, M., & Yamada, Y.
- Affiliations
- Akita University (JP)
- Corresponding author
- Yamada, Yuichiro
- Venue
- Scientific Reports
- Published
- 2021-04-28
- Volume
- 11
- Issue
- 1
- Pages
- 9167-9167
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC8080802
- OpenAlex
- W3159698927
- Cited by
- 59
- References
- 62
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 9 · 2023: 9 · 2022: 5 · 2021: 1
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- Funders
- Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (18H03171)
- the Japan Agency for Medical Research and Development (JP18ek0210111)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, liraglutide, gut microbiota, Escherichia coli, norepinephrine, sympathetic nervous system, chemical sympathectomy, intermediolateral nucleus, c-fos, bacterial translocation, colitis, tight junction gene expression, metabolic disorders
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Gastrointestinal Microbiome, Liraglutide, Fecal Microbiota Transplantation, Glucagon-Like Peptide-1 Receptor Agonists, Adrenalectomy, Animals, Appetite, Cecum, Colitis, Escherichia coli, Heat-Shock Proteins, Mice, Inbred C57BL, Norepinephrine, Sympathetic Nervous System, Proto-Oncogene Proteins c-fos, Escherichia coli Proteins, Endopeptidase Clp, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms. https://app.cochat.ai/papers/10.1038/s41598-021-88612-x
- The paper
- Kato, S., Sato, T., Fujita, H., Kawatani, M., & Yamada, Y. (2021). Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms. Scientific Reports. https://doi.org/10.1038/s41598-021-88612-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.